tyb
DDFI5899 USMC C-560- from Meacham Airport Ft. Worth on final at New Orleans NAS Joint Reserve Base Alvin Callender Field
German Military Charter DHL714 Airbus from Munich on final descent at Tokyo Narita
Hawaiian Electric Industries bought by ValueAct Capital LP: $69.82m-Mar11-13
Hawaiian Electric Industries, Inc. is a holding company with its principal subsidiaries engaged in electric utility and banking businesses operating primarily in the State of Hawaii. The Company's subsidiaries include Hawaiian Electric Company, Inc. (Hawaiian Electric) and ASB Hawaii, Inc. (ASB Hawaii). Its segments include Electric utility, Bank and Other. It operates its electric utility business through Hawaiian Electric and its subsidiaries, Hawaii Electric Light Company, Inc. (Hawaii Electric Light) and Maui Electric Company, Limited (Maui Electric). It operates its Bank segment through ASB Hawaii's subsidiary, American Savings Bank, F.S.B. (ASB). Its electric public utilities are in the business of generating, purchasing, transmitting, distributing and selling electric energy. ASB is a federally chartered savings bank providing a range of banking services to individual and business customers.
Number of employees : 3 841 people.
https://valueact.com/team/
https://www.finviz.com/insidertrading.ashx?oc=1418814&tc=7&b=2
Kala Pharmaceuticals bought by RA Capital Management LP: $49.99m-Mar 13
Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program. The Company has completed two Phase III clinical trials for KPI-121 1% . The KPI-121 0.25% is the Company’s product candidate for temporary relief of signs and symptoms of dry eye disease. KPI-121 1% is the twice-a-day product candidate for treatment of post-operative inflammation and pain following ocular surgery. MPP rTKI Program is therapies for retinal diseases that should be injected directly into the patient's eye, often at monthly intervals.
Number of employees : 136 people.
>https://www.marketscreener.com/KALA-PHARMACEUTICALS-INC-36926679/company/
https://www.finviz.com/insidertrading.ashx?oc=1346824&tc=7
https://www.racap.com/
https://www.racap.com/about-us/our-team
>never stopped doing these…bigger buys starting to show up now and there was always going to be a transition from selling to buying..that has started, in size, over the last week or so.